Andrew C. Novick, MD, chairman of the Glickman Urological and Kidney Institute at the Cleveland Clinic, recently was named a laureate of the SIU Astellas Award at the 29th Congress of the International Urological Society (SIU) in Paris. The award recognizes outstanding personal contributions to the field of urology and to its development. The award has been presented only seven times in SIU’s 100-year history.
Andrew C. Novick, MD, chairman of the Glickman Urological and Kidney Institute at the Cleveland Clinic, recently was named a laureate of the SIU Astellas Award at the 29th Congress of the International Urological Society (SIU) in Paris. The award recognizes outstanding personal contributions to the field of urology and to its development. The award has been presented only seven times in SIU’s 100-year history.
Dr. Novick joined the staff of Cleveland Clinic in 1977 as the head of the section of renal transplantation in the department of urology. In 1985, he was appointed chairman of the department of urology, which was renamed the Glickman Urological Institute in 2002. In 2006, Dr. Novick was named the inaugural holder of the Andrew C. Novick Distinguished Chair, which will be held in perpetuity by the chairman of the Glickman Urological and Kidney Institute.
Separately, Richard A. Watson, MD, director of resident education in urology and chief of ambulatory urology at Hackensack University Medical Center, Hackensack, NJ, has been honored by Prostate Net as “Clinician of the Year,” at the organization’s third annual “In The Know” Awards Ceremony at the New York University Kimmel Center for University Life.
The “In The Know” award is presented to individuals, agencies and/or corporations who have made significant strides in helping to eliminate disparities in health care delivery. Dr. Watson received the honor for his research on prostate cancer in Native American men, which focused on the barriers that many Native American men must overcome to receive adequate diagnostic and treatment services.
Ra223 plus SABR does not delay progression of oligometastatic HSPC
October 3rd 2024"The addition of radium-223 to SABR metastasis-directed therapy in low-volume bone-metastatic hormone-sensitive prostate cancer does not delay progression of disease in the RAVENS study," said Ana Kiess, MD, PhD.